<h4>Objective</h4>Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is effective in NSCLC patients with EGFR-activating or T790M mutations, but acquired resistance remains a major challenge. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.